MBX Biosciences Inc. Common Stock (MBX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business, not the story. MBX Biosciences is a clinical-stage biopharmaceutical company with 63 employees, no reported revenue, and a pipeline led by Canvuparatide in Phase 3 for chronic hypoparathyroidism. That is a binary venture, not a proven compounding machine. Its economic moat is unproven; any durable advantage must come from clinical data, regulatory approval, and eventual commercial execution, none of which is in the filed figures yet. The financials are not those of a mature business. In fiscal 2025, the year ended 2025-12-31, net income was -$87.0M and diluted EPS was -$2.38. In fiscal 2024, the year ended 2024-12-31, net income was -$61.9M and diluted EPS was -$5.82; in fiscal 2023, the year ended 2023-12-31, net income was -$32.6M and diluted EPS was -$31.96. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$37.1M and diluted EPS was -$0.78, versus -$19.4M and -$0.58 in fiscal Q2 2025, the quarter ended 2025-06-30. The loss is widening. Free cash flow is -$85.2M over the trailing twelve months, a -3.6% FCF yield, per FairStock. At the 2026-10-13 close of $49, FairStock calculates a market cap of $2.4B, P/E of -20.68, P/B of 5.74, ROE of -33.17%, ROCE of -22.08%, and a Piotroski F-Score of 0/9. The debt-to-equity ratio is only 0.01, and FairStock's Altman Z-Score is 53.89, so leverage is not the immediate issue; cash burn is. Valuation offers no Graham-style margin of safety. Paying $2.4B for no revenue and growing losses requires faith in future approvals. The FairStock score is 20/100, and the Lynch category is none because losses occurred in each of the last three years. I can admire the pipeline, but I cannot call this a bargain on the numbers shown.

In plain English: MBX Biosciences is a small drug company testing peptide medicines for hormone and metabolic problems; its main drug is in late-stage human testing for chronic hypoparathyroidism. It has no reported revenue and has lost money each year, with recent losses growing. At $49 a share and a $2.4 billion market value, the price looks expensive compared with a business that has no sales and continuing losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer